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ABSTRACT
Design: Retrospective audit.
Setting: Secondary paediatric outpatient clinic,
Tromsø, Norway.
Participants: The participants were 80 (62.5% boys
and 37.5% girls) children and adolescents with
ad i a g n o s e de g ga l l e r g yw h oh a dt ob eo na ne g g - f r e e
diet and be unable to eat any food containing any amount
of egg, including egg-containing baked goods, without
an allergic reaction to egg protein. We also included
patients who were sensitised to egg but had never been
exposed to egg or egg-containing baked goods and were
on an egg-free diet. Other atopic diseases among the
study participants were also registered.
Intervention: The vaccination took place from
November to December 2009. The patients were
vaccinated with a monovalent inﬂuenza A (H1N1)
vaccine that had an ovalbumin content <0.33 mg/ml.
They were divided into two groups, receiving the
vaccine either as a single dose or as a fractionated
dose. Patients were selected for the fractionated dose
because of their prior reaction to egg or because they
never had been exposed to egg.
Primary outcome: There were no serious adverse
reactions to the vaccine; only one mild adverse
reaction and two possible adverse reactions.
Results: Patients ranged in age from 10 months to
16.5 years. Thirty-eight (48%) patients received
a fractionated dose. Sixty-three (79%) had one or
more atopic disease apart from egg allergy. With
regard to atopy, serum speciﬁc IgE levels or skin prick
test, there were no signiﬁcant differences between the
groups receiving the vaccine as a fractionated or as
a single dose.
Conclusions: The study conﬁrmed that patients
allergic to egg can be safely vaccinated with a regular
inﬂuenza vaccine containing <0.333 mg/ml ovalbumin,
even if these patients had displayed previous
anaphylactic reactions to egg and had been diagnosed
with concurrent atopic diseases.
INTRODUCTION
In July 2009, the WHO recommended vacci-
nation against the emerging pandemic
inﬂuenza A (H1N1) virus.
1 In October 2009,
the Norwegian Health Authorities (NHA)
followed suit and recommended vaccination
of the whole Norwegian population against
the virus.
2
However, the available monovalent inﬂu-
enza A (H1N1) vaccine at the time contained
egg protein (ovalbumin) residue and the
WHO, American Center for Disease Control
and American Academy of Pediatrics all
warned that it should not be used in patients
with severe egg allergy.
3e5 An egg-free
vaccine was expected but would not be
available in Norway before the ﬁrst week of
December 2009 and then only in a very
limited number of doses.
6
An NHA-appointed advisory group recom-
mended that patients with egg allergy should
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ARTICLE SUMMARY
Article focus
- We wanted to vaccinate the children severely
affected by egg allergy with the same vaccine
that the rest of the Norwegian population was
receiving at the time and that vaccine contained
egg residue.
Key messages
- It is safe to vaccinate children with severe egg
allergy with a vaccine containing a low level of
egg residue, even if these children suffer from
concurrent atopic diseases.
- The level of serum-speciﬁc IgE to egg does not
predict a reaction to the vaccine.
- Children with a positive serum-speciﬁc IgE test
to egg allergy, who had never been exposed to
egg, should be treated as if they are allergic to
egg.
Strengths and limitations
- The strength of this study is that it is the same
doctor who thoroughly evaluated all the patients
before vaccination also evaluated the patients
with suspected reactions to the vaccine.
- A weakness is that the number of participants in
the study is quite small.
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Open Access Researchbe examined by a physician with a special competence in
allergies and that patients with anaphylactic shock reac-
tions to egg should not be vaccinated at all.
7 In addition,
it was recommended that patients who exhibit a severe
reaction to egg should be subjected to a skin prick test
(SPT) to determine whether or not the individual could
be safely vaccinated. The advisory group regarded one or
more of the following reactions to egg as severe:
angiooedema, airway oedema, asthma, urticaria, rhinitis
or vomiting.
The paediatric outpatient clinic at the University
Hospital North Norway meets about 6000 consultations
per year, and approximately half of these consultations
concern atopic diseases. In October 2009, Erlewyn-
Lajeunesse et al
8 recommended that patients allergic
to egg should receive only vaccines containing
<1.2 mg/ml ovalbumin and that a two-dose split protocol
should be used in individuals with severe egg allergy.
According to the producer, the available monovalent
inﬂuenza A (H1N1) vaccine contained <0.333 mg/ml
ovalbumin (personal correspondence with Hilde Bakke,
Regulatory Advisor at GlaxoSmithKline, Norway. 6 July
2011).
We decided to vaccinate children and adolescents
allergic to egg with the recommendations by Erlewyn-
Lajeunesse et al.
8 The only patients to be vaccinated at
the outpatient clinic were those unable to digest the
slightest amount of egg, including egg-containing baked
goods. Originally, the recommendation from the NHA
was that the patients should receive two doses of the
vaccine. However, before we could administer the
second dose, new information from the NHA became
available in December 2009, indicating that one dose of
the vaccine produced a sufﬁcient immune response.
9
The objective of this study was to determine the safety
of administering a monovalent inﬂuenza A (H1N1)
vaccine to egg allergic patients following the guidelines
in the article.
8
MATERIALS AND METHODS
Setting
The vaccination drive took place at the outpatient clinic
of the Department of Pediatrics at the University
Hospital of North Norway in Tromsø, Norway. Vaccina-
tions were administered from 4 November to 1
December 2009.
Study participants
A total of 80 children were vaccinated: 50 (62.5%) boys
and 30 (37.5%) girls. Mean age was 6 years and
3 months. Some of the patients were under our care,
while others had been referred to us for vaccination by
their general practitioner.
Criteria for inclusion in the study
There were two criteria and both had to be met. The ﬁrst
criterion was a diagnosed sensitisation to egg demon-
strated by a positive SPT or positive serum speciﬁc IgE
(SSIgE)-mediated egg allergy. The SPT was considered
positive if a weal of >3 mm formed; the SSIgE was
analysed with either the Siemens Immulite or the Phadia
ImmunoCAP (personal correspondence with Ann Karin
Lien, Immunology Lab, University Hospital North
Norway. 10 March 2011). Values >0.35 kU/l were
considered positive.
The second criterion was that the patient had to be on
an egg-free diet and be unable to eat any food
containing any amount of egg, including egg-containing
baked goods, without an allergic reaction to egg protein.
We also included patients who were sensitised to egg but
had never been exposed to egg or egg-containing baked
goods and were on an egg-free diet.
Concurrent atopic diseases
We recorded other atopic diseases in the included
patients only if they were on current medication for
asthma, allergy or eczema or if they were on a diet that
avoided food other than egg. The other atopic diseases
had been diagnosed by a physician prior to vaccination.
No other diseases than atopic diseases were recorded.
Course of action
An appointment was made for all patients at the outpa-
tient clinic. Every day, one nurse was assigned to
administer the vaccine. The same physician (BAF)
conducted all interviews, examinations and evaluations
for all patients and decided whether they should receive
a fractionated- or a single-dose vaccine. All patients were
interviewed and physically examined. A form that
contained written instructions on which type of vaccina-
tion the patient should receive was completed. Included
on the form was the dosage of intramuscular epineph-
rine, intravenous hydrocortisone and oral antihistamine
to be administered in case of a severe allergic reaction.
All the asthmatics on the programme were in a stable
phase, and all patients could be vaccinated. Two of the
children had a very severe atopic eczema at the time of
vaccination; one of them was an inpatient as a result of
severe eczema. If any reaction to the vaccine occurred
while a patient was at the outpatient clinic, it would be
recorded by the nurse and the patient would be exam-
ined by the same doctor who had conducted the initial
assessment. Every reaction except pain at the injection
site was recorded.
We adopted the approach advised in the case of mass
vaccination and took no new blood samples for the
purpose of diagnosing allergy, relying on the available
information.
Dose and administration
The vaccine dose was age dependent, 0.25 ml for those
younger than 10 years and 0.5 ml for those older than
10 years.
The enrolled patients were divided into two groups as
described by Erlewyn-Lajeunesse et al.
8 One group was
given fractionated doses of the vaccine: ﬁrst a tenth and
after 30 min the remaining nine-tenths of the dose. The
other group got the vaccine as a single dose.
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Vaccination with vaccine containing egg residueThe criterion which determined whether a patient
should receive the fractionated dose was that he or she
must have suffered from prior anaphylaxis, cardiovascular
complications or collapse when exposed to egg protein.
This included respiratory symptoms, hypotension,
circulatory shock and severe abdominal pain.
The criterion which determined whether a patient
should receive the single dose was that he or she should
have suffered from mild gastrointestinal and dermato-
logical reactions when exposed to egg protein, including
urticaria, angiooedema and vomiting.
One of the recommendations in the article was not
followed.
8 The article recommended that patients with
a known allergy to egg, but who had never been exposed
to egg in any form should get the vaccine as a single dose
at the hospital. Because the reaction of these patients to
egg was unknown, it was decided to vaccinate them with
a fractionated dose.
The patients waited 30 min between the fractionated
doses and 60 min after the ﬁnal fractionated dose. The
patients who received a single dose waited 30 min before
they leave the clinic. The patients and parents were
encouraged to provide us with feedback should a patient
experience a delayed allergic reaction after returning
home.
All patients and parents were informed that the NHA
had discouraged using this particular vaccine in indi-
viduals with egg allergy, but that there was reason to
believe that they could still be vaccinated and that some
published articles agreed.
8 They were also informed that
the vaccine was administered at the outpatient clinic
in case of an adverse reaction. Both patients and
parents expressed their conﬁdence in the treatment and
information they were given.
Statistical analysis
We used Wilcoxon rank sum test, c
2 test and Student
t test to test for statistical signiﬁcance. A p value of <0.05
was considered signiﬁcant.
RESULTS
Study population
A total of 80 (100%) patients (50 boys and 30 girls) were
enrolled and were all vaccinated. Mean age was
6.25 years, ranging from 10 months to 16.5 years. Mean
age of those getting the vaccine fractioned was 6 years
9 months and those getting single dose vaccine were
6 years 3 months (table 1).
A total of 73 patients (91%) had a positive SSIgE test,
although we did not know the exact value of the SSIgE
test in two of them. The remaining seven (9%) had
shown a reaction to egg in only the SPT. Median SSIgE
level to egg protein, for the whole group, was 17.0 kU/l.
Eleven (15%) patients had an SSIgE >99 kU/l, while 25
(35%) patients had an SSIgE between 0.8e8.3 kU/l.
Of the 80 patients, 38 (48%) were given the fraction-
ated dose and 42 (52%) received the vaccine as a single
dose. There is a statistical difference in age between the
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Vaccination with vaccine containing egg residuepatients never being exposed to egg and those having
a severe allergic reaction to egg. The groups were
indistinguishable with regard to SSIgE level and time
since the SSIgE level had been done. There was also no
difference in the median and the range of SSIgE
between the two groups. SSIgE had been measured
between 1 month and 10 years before, with a mean time
of 28.6 months. Half of the patients who had their SSIgE
measured were older than 1 year, and the SSIgE had
a median value of 25.4 kU/l.
A surprisingly high number of patients (19 (24%))
had, according to their parents, never been exposed to
egg. These patients had for some reason been tested for
egg allergy, the tests had shown elevated SSIgE to egg
protein, and consequently, they had avoided egg there-
after. The testing took place before they had an oppor-
tunity to be exposed to egg. At our clinic, patients with
suspicious allergies to other foods or a severe atopic
eczema will routinely be tested for food allergies,
including egg allergy.
A high number of patients (63 (79%)) had atopic
diseases other than those caused by egg allergy and 39
(49%) patients were on treatment for asthma. A total of
38 (48%) patients suffered from ongoing eczema.
There were 43 (54%) patients with other allergies
apart from egg allergy, including food and inhalation
allergies. Overall, these 43 patients suffered from a total
of 134 recorded allergies. Food allergies were the most
common (32 (40%) patients), while 24 (30%) of the
patients presented with an inhalation allergy.
There are no statistical signiﬁcant differences between
the groups never being exposed to egg, a severe allergy
to egg or a mild allergy to egg, regarding atopy, asthma,
food allergies other than egg allergy, inhalation allergies
or eczema.
Responses to the vaccine
All patients and their parents were encouraged to
contact the outpatient clinic after the vaccination if
a delayed allergic reaction occurred, but nobody
reported any such reaction.
Of the 80 patients enrolled in the programme, only
four displayed symptoms shortly after vaccination. Their
histories and reactions are discussed below.
Patient A (2 years 8 months old)
This patient had a mild allergic reaction to the vaccine.
The vaccine was given as a fractionated dose. The SSIgE
(measured in the month before vaccination) was
1.7 kU/l, and the patient had never before been
exposed to egg. The patient had a diagnosis of asthma
and food allergies to milk, ﬁsh, peas and peanuts. A few
minutes after the second dose, the patient displayed
a weal of 1 cm on the left side of the lower lip, a self-
limiting rash on the thighs and also had loose stools. No
cardiovascular or respiratory reaction was experienced.
The patient was given an oral antihistaminedmainly
because the travelling time to home would be longdand
left the clinic 1 h after the second dose.
Patient B (11 months old)
This patient also received a fractionated dose and showed
symptoms that could perhaps be attributed to the vaccine.
The patient had never before been exposed to egg and
had an SSIgE >99 kU/l, tested in the month before
vaccination. The patient had severe ongoing eczema and
multiple food allergies (milk, wheat, barley, oats, rye, ﬁsh
and peanuts). After the ﬁrst dose, the right ear was more
erythematous, and after the second dose, a slight swelling
developed around the eye on the same side. It was difﬁ-
cult to distinguish this response from the other eczema
symptoms as they vary signiﬁcantly. The patient displayed
no cardiovascular or respiratory reaction.
Patient C (8 years and 7 months old)
This patient showed symptoms that could perhaps be as
a result of the vaccine. The last SSIgE value (measured
3 years before vaccination) had been 14.6 kU/l, and the
patient had never been exposed to egg. The last SPTwas
done 10 months prior to vaccination and was positive
with a weal of 10 mm. The patient had a diagnosis of
asthma, inhalation allergy (grass pollen) and food
allergies (milk, ﬁsh), was given a fractionated dose and
started to sneeze after the second dose. There were no
cardiovascular symptoms, and pulmonary auscultation
also showed no bronchoconstriction. The sneezing was
self-limiting and happens regularly at home, according
to the parents.
Patient D (16 years old)
This reaction took the longest to resolve, but the symp-
toms were eventually attributed to fear of being exposed
to an egg-containing vaccine as the patient had previ-
ously had an anaphylactic reaction to egg-containing
food. The patient had a diagnosis of asthma and had an
SSIgE >99 kU/l, measured in the month before vacci-
nation. The patient had been anxious before coming to
the clinic and had skipped breakfast. The patient expe-
rienced abdominal pain after the ﬁrst fractionated dose
and had to lie down and was repeatedly examined, and
the conclusion was that there was no allergic reaction.
The vaccine was further fractionated four times, and the
last administration was six-tenths of the dose. Total time
spent at the outpatient clinic was 3 h, but the patient felt
ﬁt when leaving. The method used to vaccinate this
patient (extended fractionating) is similar to the
extended-fractionating method described in the Amer-
ican Academy of Pediatrics Committee on Infectious
Disease’s Red Book.
10 We decided on multiple fraction-
ating for this patient because the psychological symp-
toms could have masqueraded as allergic reactions. By
administering the vaccine in very small steps, the patient
felt reassured that there would be no severe allergic
reaction. Without such reassurance, the vaccination
might have become so uncomfortable for the patient
that it could have become impossible to complete.
After this incident, all the teenagers were asked if they
had had breakfast and those who did not had to eat
before being vaccinated.
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Vaccination with vaccine containing egg residueDISCUSSION AND CONCLUSIONS
Of the patients who participated in this study, one
showed a clear adverse reaction to the egg-containing
vaccine and two had a possible adverse reaction. All
reactions were mild and needed no immediate inter-
vention. Because they had an egg allergy, all the patients
in the group were considered at high risk, even more so
because 79% of them suffered from other atopic diseases
as well.
Safety of vaccination in patients allergic to egg
The study conﬁrmed that patients allergic to egg can be
safely vaccinated with a regular inﬂuenza vaccine
containing <0.333 mg/ml ovalbumin, even if these
patients had displayed previous anaphylactic reactions to
egg and had been diagnosed with concurrent atopic
diseases. By following the guidelines in the article, we
were able to vaccinate the patients allergic to egg.
8 If
future inﬂuenza vaccines were to contain considerably
larger amount of ovalbumin, we would consider using
the same guidelines as in this study.
Signiﬁcance of concurrent atopic diseases
According to the 2008 data brief by the National Center
for Health Statistics, individuals who are younger than
18 years and had food allergy have an increased risk of
other atopic diseases.
11 The increased risk is 29.4% for
asthma, 27.2% for eczema and 31.5% for inhalation
allergies. Our study population had a higher prevalence
of all these atopic diseases (asthma 49%, eczema
48%, inhalation allergy 30%, other food allergy 40%)d
in other words, they were more affected by atopic disease
than is to be expected, even in individuals allergic to egg.
Other studies investigating the safety of vaccinating
with products that contain egg residue have not consid-
ered the aspect of other concurrent atopic diseases.
12e15
Concurrent atopic diseases are of concern in vaccina-
tion, but we showed that even though our study popu-
lation was affected more heavily than one would expect,
these patients could still be safely vaccinated.
Signiﬁcance of no previous exposure to egg
The patient with an allergic reaction to the vaccine and
the two patients with possible reactions had never before
been exposed to egg. This could indicate that a cautious
approach is needed in the vaccination of individuals who
had tested positive for egg allergy but had never been
exposed to egg. When immunised with egg-containing
vaccine, these patients should be treated as if they had in
fact exhibited a reaction to egg exposure.
Signiﬁcance of SSIgE/SPT
Practitioners treating patients with food allergies should
be aware that the level of SSIgE or size of SPT does not
predict the severity of a food reaction.
16 The patients in
our study who were given the fractionated-dose vaccine
had displayed the most severe allergic reactions to egg.
Yet we found no difference in SSIgE levels of those who
received the fractionated dose and those who received
the vaccine as a single dose. This ﬁnding emphasises that
SSIgE levels should not determine whether the vaccine
should be fractionated or not.
Signiﬁcance of age
There was a signiﬁcant age difference between the
patients who had never been exposed to egg and those
with a severe reaction to egg. We believe the reason for
this is that it is difﬁcult to keep children on an egg-free
diet. The moment they are exposed to egg, they are
relegated to put in one of the two other groups, with
a known allergic reaction to egg.
Dose fractionation
In this study, we chose to vaccinate either with a frac-
tionated or a single dose. All patients tolerated the
10% dose, and ultimately received the 90% dose,
and only one patient showed a mild reaction. This
indicates that in the case of a vaccine with an ovalbumin
level of <0.333 mg/ml, all patients could in fact have
received the vaccine as a single dose without serious
complications.
Risk of overestimating allergic reactions
Every centre administering vaccines knows the protocols
that should be followed in the event of an allergic
reaction to a vaccine. When patients with prior anaphy-
lactic reactions to egg are vaccinated, it is important
that the centre administering the vaccine also has
experience of allergies. If not, allergic reactions could be
overestimated as a result of misinterpretation of symp-
toms, as could have been the case with patient D in our
study.
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